This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Greenberg, Howard
Item Type | Name |
Concept
|
Pharmacokinetics
|
Academic Article
|
MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans.
|
Academic Article
|
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
|
Academic Article
|
Pharmacokinetics of intramuscularly administered ertapenem.
|
Academic Article
|
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
|
Academic Article
|
The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers.
|
Academic Article
|
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
|
Academic Article
|
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
|
Academic Article
|
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.
|
Academic Article
|
The pharmacokinetics of taurolidine metabolites in healthy volunteers.
|
Academic Article
|
Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
|
Academic Article
|
American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
|
Academic Article
|
Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.
|
Academic Article
|
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
|
Academic Article
|
Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
|
Academic Article
|
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
|
Academic Article
|
Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency.
|